JP2017512759A - 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 - Google Patents

抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 Download PDF

Info

Publication number
JP2017512759A
JP2017512759A JP2016554855A JP2016554855A JP2017512759A JP 2017512759 A JP2017512759 A JP 2017512759A JP 2016554855 A JP2016554855 A JP 2016554855A JP 2016554855 A JP2016554855 A JP 2016554855A JP 2017512759 A JP2017512759 A JP 2017512759A
Authority
JP
Japan
Prior art keywords
antibody
antigen
amino acid
acid sequence
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016554855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512759A5 (2
Inventor
ライ，ジァン−シュン
チェン，イ−ジュ
ワン，チェン−チ
ツァイ，ユィ−チェン
ユー，チェン−ダー，トニー
Original Assignee
オービーアイ ファーマ インコーポレイテッド
オービーアイ ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オービーアイ ファーマ インコーポレイテッド, オービーアイ ファーマ インコーポレイテッド filed Critical オービーアイ ファーマ インコーポレイテッド
Publication of JP2017512759A publication Critical patent/JP2017512759A/ja
Publication of JP2017512759A5 publication Critical patent/JP2017512759A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
JP2016554855A 2014-04-10 2015-04-10 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 Pending JP2017512759A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US61/977,824 2014-04-10
US201462057381P 2014-09-30 2014-09-30
US62/057,381 2014-09-30
PCT/US2015/025305 WO2015157629A2 (en) 2014-04-10 2015-04-10 Antibodies, pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2017512759A true JP2017512759A (ja) 2017-05-25
JP2017512759A5 JP2017512759A5 (2) 2019-06-27

Family

ID=54288553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554855A Pending JP2017512759A (ja) 2014-04-10 2015-04-10 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途

Country Status (17)

Country Link
US (2) US9902779B2 (2)
EP (2) EP3129048B1 (2)
JP (1) JP2017512759A (2)
KR (1) KR101966408B1 (2)
CN (2) CN112390887B (2)
AU (2) AU2015243246B2 (2)
BR (1) BR112016020009A2 (2)
CA (2) CA2941029C (2)
CL (1) CL2016002569A1 (2)
ES (1) ES2772817T3 (2)
IL (2) IL246837B (2)
PH (1) PH12016501976A1 (2)
RU (1) RU2016138744A (2)
SG (1) SG11201607258SA (2)
TW (3) TWI697503B (2)
WO (1) WO2015157629A2 (2)
ZA (1) ZA201605175B (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528844A (ja) * 2019-03-28 2022-06-16 オービーアイ ファーマ，インコーポレイテッド グロボ－ｈ関連がん療法のためのコンパニオン診断アッセイ
US12090212B2 (en) 2016-11-21 2024-09-17 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014391422A1 (en) 2013-09-17 2015-12-17 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
EP3119424A4 (en) 2014-03-19 2017-09-13 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
CA2941029C (en) 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
KR20180050339A (ko) 2015-09-04 2018-05-14 오비아이 파머 인코퍼레이티드 글리칸 어레이 및 사용 방법
KR20180077181A (ko) 2015-10-07 2018-07-06 오비아이 파머 인코퍼레이티드 신규한 탄수화물 항체, 약제학적 조성물 및 이들의 용도
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109379889A (zh) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
WO2018023121A1 (en) 2016-07-29 2018-02-01 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
EP3630182A4 (en) * 2017-05-24 2021-02-24 Development Center for Biotechnology HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT
EP3765031A4 (en) 2018-03-14 2022-03-23 Memorial Sloan Kettering Cancer Center ANTI-POLYSIAL ACID ANTIBODIES AND USES THEREOF
WO2019232519A1 (en) * 2018-06-01 2019-12-05 Obi Pharma, Inc. Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CA3204922A1 (en) * 2021-02-09 2022-08-18 Ming-Tain Lai Globo series antigens-binding chimeric antigen receptors and uses thereof
WO2026052782A1 (en) 2024-09-06 2026-03-12 Tacalyx Gmbh Anti-globo h antibodies

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
CN1423700A (zh) 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
DE60124912T2 (de) * 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
JP4335130B2 (ja) * 2002-04-30 2009-09-30 協和発酵キリン株式会社 ヒトインスリン様成長因子に対する抗体
DE60334453D1 (de) * 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
EP2287195B1 (en) * 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
KR100958505B1 (ko) 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
BRPI0519596B1 (pt) * 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
AU2006211037B2 (en) * 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
AU2006230099B2 (en) * 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
CN102065868A (zh) 2008-06-16 2011-05-18 中央研究院 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
ES2477549T3 (es) 2008-06-16 2014-07-17 Academia Sinica Diagnóstico del cáncer según la concentración de anticuerpos contra Globo H y sus fragmentos
TWI392502B (zh) * 2009-06-16 2013-04-11 Academia Sinica 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CN102884085B (zh) 2010-04-09 2016-08-03 Aveo制药公司 抗erbb3抗体
CN103459600B (zh) * 2010-07-01 2016-10-19 帝斯曼知识产权资产管理有限公司 用于生产感兴趣的化合物的方法
US8999343B2 (en) * 2010-08-16 2015-04-07 Amgen Inc. Antibodies that bind myostatin, compositions and methods
WO2012088094A2 (en) * 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
EP2497782A1 (en) * 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3119424A4 (en) 2014-03-19 2017-09-13 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
CA2941029C (en) 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GLYCOCONJUGATE JOURNAL, vol. 15, JPN6019006181, 1998, pages 243 - 249, ISSN: 0004133306 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12090212B2 (en) 2016-11-21 2024-09-17 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
JP2022528844A (ja) * 2019-03-28 2022-06-16 オービーアイ ファーマ，インコーポレイテッド グロボ－ｈ関連がん療法のためのコンパニオン診断アッセイ
JP7628959B2 (ja) 2019-03-28 2025-02-12 オービーアイ ファーマ，インコーポレイテッド グロボ－ｈ関連がん療法のためのコンパニオン診断アッセイ

Also Published As

Publication number Publication date
CN106456727B (zh) 2020-11-27
BR112016020009A2 (pt) 2017-10-17
TW201738277A (zh) 2017-11-01
CA2941029A1 (en) 2015-10-15
US20170029526A1 (en) 2017-02-02
TWI695013B (zh) 2020-06-01
AU2015243246B2 (en) 2018-09-06
PH12016501976A1 (en) 2016-12-19
TWI609886B (zh) 2018-01-01
ZA201605175B (en) 2017-09-27
IL276695B (en) 2021-09-30
TW201546092A (zh) 2015-12-16
IL246837A0 (en) 2016-08-31
AU2018253589A1 (en) 2018-11-22
KR101966408B1 (ko) 2019-04-05
EP3129048A4 (en) 2017-10-25
ES2772817T3 (es) 2020-07-08
IL276695A (en) 2020-09-30
CL2016002569A1 (es) 2017-09-08
AU2018253589B2 (en) 2020-04-16
US10815307B2 (en) 2020-10-27
SG11201607258SA (en) 2016-10-28
KR20160137984A (ko) 2016-12-02
TW201738276A (zh) 2017-11-01
CN112390887A (zh) 2021-02-23
CN112390887B (zh) 2023-09-26
IL246837B (en) 2020-08-31
EP3129048A2 (en) 2017-02-15
RU2016138744A (ru) 2018-05-11
AU2015243246A1 (en) 2016-09-08
WO2015157629A3 (en) 2015-12-03
CA2941029C (en) 2021-02-16
EP3129048B1 (en) 2020-01-15
WO2015157629A2 (en) 2015-10-15
US9902779B2 (en) 2018-02-27
RU2016138744A3 (2) 2018-05-11
TWI697503B (zh) 2020-07-01
CA3104268A1 (en) 2015-10-15
CN106456727A (zh) 2017-02-22
US20180134799A1 (en) 2018-05-17
EP3662928A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
JP2017512759A (ja) 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
US11236154B2 (en) Carbohydrate antibodies, pharmaceutical compositions and uses thereof
TWI811604B (zh) 抗體、醫藥組成物及其用途
JP7353187B2 (ja) 抗ｌ１－ｃａｍ抗体およびその使用
JP2012525432A (ja) ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
JP2016006026A (ja) テトラスパニン８に対するハイブリドーマクローンおよびモノクローナル抗体
CN114761042A (zh) Il-38特异性抗体
CN117946270B (zh) 抗cd93抗体及其用途
HK40037463A (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK1232767A1 (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK40037463B (zh) 抗体、产生所述抗体的杂交瘤、及其用途
HK1232767B (zh) 抗体、产生所述抗体的杂交瘤、及其用途
TW202302635A (zh) Ｉｌ－３８專一性抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200213

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200325

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200331

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200703

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200707

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201124

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210302

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210706

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20210706

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210720

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211109

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211214

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211214